Targeting AMPK in the treatment of malignancies

Journal of Cellular Biochemistry

Volumn 113, Issue 2, 2012, Pages 404-409

  Vakana, Eliza ^a   Altman, Jessica K ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

AMPK; Cancer; mTOR

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; B RAF KINASE; CISPLATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; NUTLIN 3; PHENFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER REGRESSION; CARCINOGENESIS; CELL CYCLE ARREST; CELL METABOLISM; CELL PROLIFERATION; COLON CANCER; ENZYME ACTIVITY; GENE INACTIVATION; GENE MUTATION; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LEUKEMIA CELL; LUNG CANCER; LUNG CARCINOGENESIS; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER;

ADENYLATE KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; METFORMIN; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84855519804     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23369     Document Type: Review

References (73)

1. Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R. 2007. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 313(16):3592-3603. (Pubitemid 47404540)
2. Bjornsti MA, Houghton PJ. 2004. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4(5):335-348. (Pubitemid 38579480)
3. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85-95.
4. Carling D, Sanders MJ, Woods A. 2008. The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes 32 (Suppl. 4): S55-S59.
5. Carling D, Mayer FV, Sanders MJ, Gamblin SJ. 2011. AMP-activated protein kinase: Nature's energy sensor. Nat Chem Biol 7(8):512-518.
6. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, Maestre L, Conde E, Lopez-Rios F, Clevers HC, Sanchez-Cespedes M. 2007. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26:1616-1625. (Pubitemid 46398737)
7. Chen MB, Shen WX, Yang Y, Wu XY, Gu JH, Lu PH. 2011. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J Cell Physiol 226:1915-1925.
8. Choi HJ, Kim TY, Chung N, Yim JH, Kim WG, Kim J, Kim WB, Shong YK. 2011. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside (AICAR). J Endocrinol [Epub ahead of print].
9. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, Zhao G, Marsh K, Kym P, Jung P, Camp HS, Frevert E. 2006. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403-416. (Pubitemid 43811782)
10. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 1995. 5-Aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMPactivated protein kinase in intact cells? Eur J Biochem 229(2):558-565.
11. Dancey J. 2010. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4):209-219.
12. Davies SP, Hawley SA, Woods A, Carling D, Haystead TA, Hardie DG. 1994. Purification of the AMP-activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. Eur J Biochem 223(2):351-357. (Pubitemid 24244180)
13. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. 2009. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia 23:784-790.
14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503): 1304-1305. (Pubitemid 40813563)
15. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. 2008. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110(2):246-250.
16. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J. 2010. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116:4262-4273.
17. Green MF, Anderson KA, Means AR. 2011. Characterization of the CaMKK-beta- AMPK signaling complex. Cell Signal [Epub ahead of print].
18. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. 2009. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 106: 12932-12937.
19. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE, Shaw RJ. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30:214-226. (Pubitemid 351626684)
20. Hadad SM, Fleming S, Thompson AM. 2008. Targeting AMPK: A new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67:1-7.
21. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM. 2009. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9:307.
22. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM. 2011. Evidence for biological effects of metformin in operable breast cancer: A preoperative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783-794.
23. Hager M, Haufe H, Kemmerling R, Hitzl W, Mikuz G, Moser PL, Kolbitsch C. 2009. Increased activated Akt expression in renal cell carcinomas and prognosis. J Cell Mol Med 13(8B):2181-2188.
24. Hardie DG. 2011. Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 93(4):891S-896S.
25. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. 1996. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271:27879-27887. (Pubitemid 26367365)
26. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG. 2005. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2:9-19. (Pubitemid 43239821)
27. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507-7511.
28. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. 2007. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281. (Pubitemid 46849157)
29. Inoki K, Li Y, Zhu T, Wu J, Guan KL. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4(9):648-657. (Pubitemid 34993700)
30. Janjetovic K, Vucicevic L, Misirkic M, Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S, Bumbasirevic V, Trajkovic V, Harhaji-Trajkovic L. 2011a. Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol 651:41-50.
31. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D, Trajkovic V. 2011b. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol [Epub ahead of print].
32. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson BE, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardeesy N, Sharpless NE, Wong KK. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448:807-810. (Pubitemid 47266337)
33. Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. 2007. Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Res 67:11630-11639.
34. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27(20):3297-3302.
35. Jorgensen SB, Richter EA, Wojtaszewski JF. 2006. Role of AMPK in skeletal muscle metabolic regulation and adaptation in relation to exercise. J Physiol 574:17-31. (Pubitemid 43905793)
36. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. 2010. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11:390-401.
37. Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH, Jeon YJ, Lee CH, Park J, Chang WY, Hyun JW. 2010. Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol 30(2):134-140.
38. Kim EK, Park JM, Lim S, Choi JW, Kim HS, Seok H, Seo JK, Oh K, Lee DS, Kim KT, Ryu SH, Suh PG. 2011. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J Biol Chem 286:24036-24045.
39. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. 2009. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545.
40. Lea MA, Chacko J, Bolikal S, Hong JY, Chung R, Ortega A, desbordes C. 2011. Addition of 2-deoxyglucose enhances growth inhibition but reverses acidification in colon cancer cells treated with phenformin. Anticancer Res 31(2): 421-426.
41. Lee YK, Park OJ. 2010. Regulation of mutual inhibitory activities between AMPK and Akt with quercetin in MCF-7 breast cancer cells. Oncol Rep 24(6):1493-1497.
42. Lin JN, Lin VC, Rau KM, Shieh PC, Kuo DH, Shieh JC, Chen WJ, Tsai SC, Way TD. 2010. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J Agric Food Chem 58(3): 1584-1592.
43. Linehan WM, Srinivasan R, Schmidt LS. 2010. The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol 7(5):277-285.
44. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. 2009. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13):2031-2040.
45. Liu J, Li M, Song B, Jia C, Zhang L, Bai X, Hu W. 2011. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol [Epub ahead of print].
46. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. 2010. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res 3:1066-1076.
47. Merrill GF, Kurth EJ, Hardie DG, Winder WW. 1997. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 273 (6 Pt 1): E1107-E1112.
48. Mitchelhill KI, Stapleton D, Gao G, House C, Michell B, Katsis F, Witters LA, Kemp BE. 1994. Mammalian AMP-activated protein kinase shares structural and functional homology with the catalytic domain of yeast Snf1 protein kinase. J Biol Chem 269(4):2361-2364. (Pubitemid 24235720)
49. Mor V, Unnikrishnan MK. 2011. 5'-adenosine monophosphate-activated protein kinase and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 1(3):206-216.
50. O'Regan R, Hawk NN. 2011. mTOR inhibition in breast cancer: Unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 15(7):859-872.
51. Ouyang J, Parakhia RA, Ochs RS. 2011. Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286:1-11.
52. Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 (Pt 3): 607-614. (Pubitemid 30410251)
53. Priebe A, Tan L, Wahl H, Kueck A, He G, Kwok R, Opipari A, Liu JR. 2011. Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol 122(2): 389-395.
54. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. 2011a. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13:483-491.
55. Rattan R, Giri S, Hartmann LC, Shridhar V. 2011. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 15(1):166-178.
56. Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P. 2009. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PloS One 4:e7889.
57. Rutter GA, Leclerc I. 2009. The AMP-regulated kinase family: Enigmatic targets for diabetes therapy. Mol Cell Endocrinol 297(1-2):41-49.
58. Sabatini DM. 2006. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 6(9):729-734. (Pubitemid 44286004)
59. Sanli T, Rashid A, Liu C, Harding S, Bristow RG, Cutz JC, Singh G, Wright J, Tsakiridis T. 2010. Ionizing radiation activates AMP-activated kinase (AMPK): A target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys 2010. 78(1):221-229.
60. Sanli T, Liu C, Rashid A, Hopmans SN, Tsiani E, Schultz C, Farrell T, Singh G, Wright J, Tsakiridis T. 2011. Lovastatin sensitizes lung cancer cells to ionizing radiation: Modulation of molecular pathways of radioresistance and tumor suppression. J Thorac Oncol 6(3):439-450.
61. Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger A, Gil J. 2010. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 116:3023-3032.
62. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F. 2009. Inhibition of PI3KAKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129:1500-1515.
63. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC. 2007. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4- ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: Implication for targeted therapy. Mol Cancer 6:46.
64. Viollet B, Lantier L, Devin-Leclerc J, Hebrard S, Amouyal C, Mounier R, Foretz M, Andreelli F. 2009. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front Biosci 14:3380-3400.
65. Woodard J, Sassano A, Hay N, Platanias LC. 2008. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 14(14):4640-4649.
66. Woodard J, Joshi S, Viollet B, Hay N, Platanias LC. 2010. AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 10(11):1168-1177.
67. Woodard J, Platanias LC. 2010. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biohys Res Commun 398:135-139.
68. Yuan HD, Quan HY, Zhang Y, Kim SH, Chung SH. 2010. 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Report 3(5):825-831.
69. Xiao B, Sanders MJ, Underwood E, Heath R, Mayer FV, Carmena D, Jing C, Walker PA, Eccleston JF, Haire LF, Saiu P, Howell SA, Aasland R, Martin SR, Carling D, Gamblin SJ. 2011. Structure of mammalian AMPK and its regulation by ADP. Nature 472:230-233.
70. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. 2006. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273. (Pubitemid 44799743)
71. Zhang BB, Zhou G, Li C. 2009. AMPK: An emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9(5):407-416.
72. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, Cantley LC. 2009. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33:237-247.
73. Zhuang Y, Miskimins WK. 2008. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18.